Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;11(4):227-37.
doi: 10.1631/jzus.B0900327.

Urinary proteomics as a novel tool for biomarker discovery in kidney diseases

Jing Wu  1 , Yi-ding Chen, Wei Gu
Affiliations
Review

Urinary proteomics as a novel tool for biomarker discovery in kidney diseases

Jing Wu et al. J Zhejiang Univ Sci B. 2010 Apr.

Abstract

Urine has become one of the most attractive biofluids in clinical proteomics, for its procurement is easy and noninvasive and it contains sufficient proteins and peptides. Urinary proteomics has thus rapidly developed and has been extensively applied to biomarker discovery in clinical diseases, especially kidney diseases. In this review, we discuss two important aspects of urinary proteomics in detail, namely, sample preparation and proteomic technologies. In addition, data mining in urinary proteomics is also briefly introduced. At last, we present several successful examples on the application of urinary proteomics for biomarker discovery in kidney diseases, including diabetic nephropathy, IgA nephropathy, lupus nephritis, renal Fanconi syndrome, acute kidney injury, and renal allograft rejection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Four different types of MS-based proteomic technologies (a) 2DE-MS; (b) SELDI-MS; (c) LC-MS; (d) CE-MS
Fig. 1
Fig. 1
Four different types of MS-based proteomic technologies (a) 2DE-MS; (b) SELDI-MS; (c) LC-MS; (d) CE-MS
Fig. 1
Fig. 1
Four different types of MS-based proteomic technologies (a) 2DE-MS; (b) SELDI-MS; (c) LC-MS; (d) CE-MS
Fig. 1
Fig. 1
Four different types of MS-based proteomic technologies (a) 2DE-MS; (b) SELDI-MS; (c) LC-MS; (d) CE-MS
See this image and copyright information in PMC

References

    1. Ahmed FE. Utility of mass spectrometry for proteome analysis: Part II. Ion-activation methods, statistics, bioinformatics and annotation. Expert Rev Proteomics. 2009;6(2):171–197. doi: 10.1586/epr.09.4. - DOI - PubMed
    1. Bellei E, Rossi E, Lucchi L, Uggeri S, Albertazzi A, Tomasi A, Iannone A. Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. Proteomics Clin Appl. 2008;2(4):478–491. doi: 10.1002/prca.200780109. - DOI - PubMed
    1. Caiazzo RJJr, Maher AJ, Drummond MP, Lander CI, Tassinari OW, Nelson BP, Liu BCS. Protein microarrays as an application for disease biomarkers. Proteomics Clin Appl. 2009;3(2):138–147. doi: 10.1002/prca.200800149. - DOI - PubMed
    1. Cutillas PR, Norden AG, Cramer R, Burlingame AL, Unwin RJ. Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. Clin Sci (Lond) 2003;104(5):483–490. doi: 10.1042/CS20020342. - DOI - PubMed
    1. Dakna M, He Z, Yu WC, Mischak H, Kolch W. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13):1250–1258. doi: 10.1016/j.jchromb.2008.10.048. - DOI - PubMed

Publication types